BBLG Stock Overview
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bone Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.77 |
| 52 Week High | US$72.00 |
| 52 Week Low | US$1.56 |
| Beta | 0.58 |
| 1 Month Change | -20.27% |
| 3 Month Change | -46.36% |
| 1 Year Change | -97.16% |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| BBLG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.9% | -4.2% | -3.7% |
| 1Y | -97.2% | -2.0% | 20.5% |
Return vs Industry: BBLG underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: BBLG underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| BBLG volatility | |
|---|---|
| BBLG Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBLG's share price has been volatile over the past 3 months.
Volatility Over Time: BBLG's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2 | Jeff Frelick | www.bonebiologics.com |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Bone Biologics Corporation Fundamentals Summary
| BBLG fundamental statistics | |
|---|---|
| Market cap | US$1.54m |
| Earnings (TTM) | -US$8.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs BBLG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBLG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.95m |
| Earnings | -US$8.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BBLG perform over the long term?
See historical performance and comparison